At the time of baseline visits, sodium–glucose cotransporter 2 (SGLT2) inhibitors were not yet as established in the treatment of people with diabetes and cardiorenal protection as they are now, thus none of the included participants had an SGLT2 inhibitor in their prescription and consequently we were not able to analyse adherence to SGLT2 inhibitors. Here, SLC5A2 is linked to diabetes mellitus.